Glucophage

Glucophage is the original brand name for metformin hydrochloride, the premier oral biguanide antihyperglycemic agent used worldwide as a first-line treatment for managing blood glucose levels. Unlike sulfonylureas or insulin secretagogues, Glucophage does not stimulate pancreatic beta cells to produce more insulin, significantly lowering the risk of hypoglycemia when used as monotherapy. Its primary metabolic mechanisms include:

• Decreased Hepatic Gluconeogenesis: Inhibiting the liver’s production and release of excess glucose.

• Enhanced Insulin Sensitivity: Increasing peripheral glucose uptake and utilization in skeletal muscle and adipose tissue.

• Reduced Intestinal Glucose Absorption: Slowing down the absorption rate of carbohydrates across the gastrointestinal tract.

Primary Medical Indications

Glucophage is indicated for adult and pediatric populations (aged 10 years and older) for several metabolic and endocrine conditions:

• Type 2 Diabetes Mellitus: First-line pharmacotherapy alongside lifestyle, diet, and exercise modifications to improve glycemic control in adults and children.

• Prediabetes Management: Used off-label or under approved protocols to slow or prevent progression to type 2 diabetes in high-risk individuals.

• Polycystic Ovary Syndrome (PCOS): Used off-label to manage insulin resistance, reduce hyperandrogenism, regulate menstrual cycles, and induce ovulation.

• Weight Management in Metabolic Syndrome: Off-label use to limit weight gain associated with insulin resistance or second-generation antipsychotic medications.

Key Product Specifications & Dosing Forms

Critical Safety Guidelines & Precautions

• Boxed Warning for Lactic Acidosis: Metformin accumulation can cause lactic acidosis, a severe and potentially fatal metabolic complication. Primary risk factors include renal impairment (eGFR less than 30 mL/min/1.73 $\text{m}^2$), severe hepatic failure, acute heart failure, sepsis, and heavy alcohol intake.

• Gastrointestinal Side Effects: Nausea, abdominal discomfort, flatulence, bloating, and diarrhea are common during treatment initiation. Doses should be started low and titrated gradually to build tolerance.

• Contrast Dye Interruption: Glucophage must be temporarily discontinued prior to or at the time of intravascular iodinated contrast radiological procedures in patients with eGFR between 30 and 60 mL/min/1.73 $\text{m}^2$ or a history of liver disease/alcoholism.

• Vitamin $B_{12}$ Monitoring: Long-term use can decrease vitamin $B_{12}$ absorption, potentially leading to megaloblastic anemia or peripheral neuropathy. Routine serum $B_{12}$ screening is recommended every 1 to 2 years.